Evidence map›Paper›PMID 40825509›Full record

ArticleMucosal immunology2025

Clostridioides difficile toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activity.

Jeffrey R Maslanka, Jennifer A Londregan, Joshua E Denny, Ellie N Hulit, Nontokozo V Mdluli, F Christopher Peritore-Galve, Md Zahidul Alam, Mohamad-Gabriel Alameh, D Borden Lacy, Joseph P Zackular and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

11 authors.

Jeffrey R MaslankaDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.
Jennifer A LondreganImmunology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Joshua E DennyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ellie N HulitDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nontokozo V MdluliDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
F Christopher Peritore-GalveDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Md Zahidul AlamDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mohamad-Gabriel AlamehDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
D Borden LacyDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA.
Joseph P ZackularDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Protective Immunity, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael C AbtInstitute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: Michael.abt@pennmedicine.upenn.edu.

Funding

Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile VaccinesU19AI174999 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Dana Borden Lacy · 2023 to 2026
$7.9M
Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infectionU19AI174998 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DREW WEISSMAN · 2023 to 2026
$7.6M
Structural mechanisms of Clostridium difficile pathogenesisR01AI095755 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LACY, DANA BORDEN · 2011 to 2020
$3.9M
Structural Mechanisms of Clostridioides difficile pathogenesisR37AI095755 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Dana Borden Lacy · 2021 to 2026
$3.2M
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantationR01AI158830 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ABT, MICHAEL C. · 2021 to 2025
$2.4M
BLRD VA I01 BX002943NIAID NIH HHS R01 AI095755NIAID NIH HHS R01 AI158830NIAID NIH HHS R37 AI095755NIAID NIH HHS U19 AI174998NIAID NIH HHS U19 AI174999
6 · The paper itself

Abstract

Clostridioides difficile colonizes the gastrointestinal tract and secretes two virulence factors: toxin A (TcdA) and toxin B (TcdB). Protective immunity against C. difficile infection is limited as patients are susceptible to multiple rounds of recurrent infections. The factors determining whether immunity to TcdA and TcdB is generated remain incompletely defined. We determined that C. difficile-infected mice generate antibody and IL-17A-producing CD4

Indexed as

Bacterial ProteinsBacterial ToxinsCD4-Positive T-LymphocytesClostridioides difficileClostridium InfectionsEnterotoxinsGlucosyltransferasesAdaptive ImmunityAnimalsAntibodies, BacterialDisease Models, AnimalHumansInterleukin-17MiceMice, Inbred C57BLAntibodies, BacterialBacterial ProteinsBacterial ToxinsEnterotoxinsGlucosyltransferasesInterleukin-17tcdA protein, Clostridium difficiletoxB protein, Clostridium difficileClostridioides difficileIgAIntestinal CD4 T cellsMucosal ImmunologyToxins

Identifiers

PMID40825509
PMCPMC12767507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.